UNITED COMMUNITY BANKS INC
United Community Banks is a bank holding company headquartered in Greenville, South Carolina. Through its principal subsidiary, United Community Bank, it provides financial services to commercial, retail, governmental, educational, energy, health care and real estate customers. Its services include deposit accounts, secured and unsecured lending, residential mortgages, payment processing, equipment finance, private banking, wealth management, trust, investment advisory and insurance services. It serves customers through branches, other offices, internet and mobile applications, with banking operations in Georgia, South Carolina, North Carolina, Tennessee, Florida and Alabama and national SBA/USDA lending and equipment finance businesses. United Community Banks makes money primarily through banking activities, including lending and deposits, and also provides mortgage, equipment finance, wealth management, trust, insurance, reinsurance and merchant payment processing services. Its United Community Private Wealth division offers investment management, financial and estate planning, and related products; United Community Insurance operates as an independent insurance agency.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
UCB has chosen Veeva Systems' (VEEV) Veeva Vault CRM as its customer engagement platform, strengthening their partnership. The system is designed for life sciences companies, aiming to enhance commercial execution. Financial details and timelines were not disclosed.
Companies linked to UCB Chairman Sharif Zahir plan to buy shares worth Tk 103.04 crore at today's closing price of Tk 9.20. Bangladesh Bank eased UCB's shareholding limit to 30% to strengthen its capital base and attract investments. UCB is also pursuing a Tk 775 crore rights share issue and a Tk 800 crore subordinated bond.
UCB, a Belgian drug developer, is investing $2 billion to build a biologics manufacturing campus in Georgia, its first U.S. plant. The project, expected to create 330 jobs and complete by 2033, will use advanced technologies. UCB cited Georgia's life sciences support and workforce as key factors.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning UCB (UNITED COMMUNITY BANKS INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent UCB coverage spans earnings, financial news and corporate actions.
In the last 30 days, UCB insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($50K). The most active reporter was BRADSHAW RICHARD, EVP, Chief Banking Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Neutral to mildly positive as the CRM upgrade may improve commercial execution but no cost or timing details are given.
Related parties plan sizable open-market purchases after Bangladesh Bank eased UCB’s ownership cap, likely supporting near-term demand and sentiment.
The new plant could boost UCB's U.S. production capacity and long‑term revenue, but benefits will materialize years later.
Guidance lift suggests higher future earnings and may drive the stock higher.
Earnings beat core growth expectations; asset sales may boost capital ratios.
AlphAI scores every news story that mentions UCB with an AI model for sentiment and relevance, and aggregates insider trades from UNITED COMMUNITY BANKS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
UCB has chosen Veeva Systems' (VEEV) Veeva Vault CRM as its customer engagement platform, strengthening their partnership. The system is designed for life sciences companies, aiming to enhance commercial execution. Financial details and timelines were not disclosed.
Companies linked to UCB Chairman Sharif Zahir plan to buy shares worth Tk 103.04 crore at today's closing price of Tk 9.20. Bangladesh Bank eased UCB's shareholding limit to 30% to strengthen its capital base and attract investments. UCB is also pursuing a Tk 775 crore rights share issue and a Tk 800 crore subordinated bond.
UCB, a Belgian drug developer, is investing $2 billion to build a biologics manufacturing campus in Georgia, its first U.S. plant. The project, expected to create 330 jobs and complete by 2033, will use advanced technologies. UCB cited Georgia's life sciences support and workforce as key factors.
UCB raised its 2026 financial outlook, expecting revenue growth in the low twenties percentage range (€9.1B-€9.3B) and adjusted EBITDA growth in the low-to-mid forties percentage range (€3.5B-€3.6B), driven by strong US sales of Bimzelx and Cimzia. The guidance exceeds analyst expectations of €8.7B revenue and €3.03B adjusted EBITDA.
United Community Banks (UCB) reported Q3 with 9.8% annualized core loan growth and 8.0% annualized core deposit growth. The bank sold Navitas for $2.0B, sold $2.5B of low-yield securities, and acquired Peach State. Margin remained stable after six quarters of expansion.
UNITED COMMUNITY BANKS INC (UCB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 For Immediate Release For more information: Tom Speir Chief Financial Officer (864) 240-6208 Investor_Relations@ucbi.com United Community Banks, Inc. Reports Third Quarter Earnings Third Quarter Results Reflect Execution of Significant Strategic Initiatives, Strong C
United Community Banks (UCB) reports Q3 earnings tomorrow. Last quarter, revenue grew 7.4% YoY to $280.5M, meeting expectations, but EPS missed. Analysts expect 2.3% YoY revenue growth this quarter. Peers Independent Bank and Regions Financial beat estimates. UCB's stock is down 1.3% in the last month, with an average price target of $40.17.
UCB announced FDA approval for an autoinjector option for ZILBRYSQ, a treatment for generalized myasthenia gravis. The autoinjector, expected to launch in Q1 2027, offers a second self-administration method alongside the prefilled syringe. The approval was supported by clinical studies demonstrating effectiveness and safety. UCB's stock is traded on Euronext Brussels under the ticker UCB.
United Community Banks (UCB) has scheduled its Q3 2026 earnings release for October 20. The stock has seen mixed performance, with a 6% YTD gain but a 6% drop over the past quarter. Analysts estimate a fair value of $39.83, suggesting a 16% undervaluation at the current price of $33.35. The bank's diversification efforts aim to stabilize earnings and mitigate risks.
UCB presented data at the EADV 2026 Congress showing earlier treatment with Bimzelx leads to higher resolution rates in hidradenitis suppurativa. At three years, 47.4% of early-treated patients achieved IHS4-100, compared to 33.3% of late-treated patients. Biotherapy-naive patients saw up to 78.8% complete resolution of draining tunnels. The company is expanding its presence beyond this condition.
